Urogen Pharma (URGN) Projected to Release Earnings on Wednesday

Urogen Pharma (NASDAQ:URGN) is anticipated to issue its Q2 2026 results before the market opens on Wednesday, August 5th. Analysts expect the company to post earnings of ($0.2650) per share and revenue of $63.5460 million for the quarter. Individuals can check the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Wednesday, August 5, 2026 at 10:00 AM ET.

Urogen Pharma (NASDAQ:URGN) last released its quarterly earnings data on Thursday, May 7th. The company reported ($0.47) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.48) by $0.01. The business had revenue of $50.96 million during the quarter, compared to the consensus estimate of $44.83 million. On average, analysts expect Urogen Pharma to post $-1 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Urogen Pharma Trading Up 1.2%

URGN traded up $0.48 during trading on Tuesday, hitting $39.07. 109,459 shares of the company’s stock traded hands, compared to its average volume of 779,588. The company’s 50 day simple moving average is $35.18 and its two-hundred day simple moving average is $26.46. Urogen Pharma has a 12-month low of $15.86 and a 12-month high of $43.93. The stock has a market capitalization of $1.90 billion, a price-to-earnings ratio of -14.21 and a beta of 1.57.

Analysts Set New Price Targets

URGN has been the subject of several recent analyst reports. The Goldman Sachs Group restated a “neutral” rating and issued a $44.00 price target on shares of Urogen Pharma in a research note on Wednesday, July 15th. Jefferies Financial Group upgraded Urogen Pharma to a “strong-buy” rating in a report on Friday, April 24th. LADENBURG THALM/SH SH started coverage on Urogen Pharma in a research report on Monday, May 11th. They issued a “buy” rating and a $43.00 target price for the company. UBS Group reissued a “buy” rating on shares of Urogen Pharma in a research report on Thursday, July 9th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Urogen Pharma in a research note on Friday, July 17th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Urogen Pharma has a consensus rating of “Moderate Buy” and an average price target of $41.62.

Insiders Place Their Bets

In other Urogen Pharma news, insider Mark Schoenberg sold 10,000 shares of the business’s stock in a transaction on Thursday, July 9th. The shares were sold at an average price of $40.00, for a total transaction of $400,000.00. Following the completion of the sale, the insider directly owned 119,763 shares in the company, valued at approximately $4,790,520. The trade was a 7.71% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 25,222 shares of company stock worth $892,661. 4.80% of the stock is currently owned by insiders.

Institutional Trading of Urogen Pharma

Large investors have recently modified their holdings of the company. Osaic Holdings Inc. lifted its holdings in Urogen Pharma by 491.2% in the second quarter. Osaic Holdings Inc. now owns 3,695 shares of the company’s stock valued at $50,000 after acquiring an additional 3,070 shares during the period. Russell Investments Group Ltd. grew its stake in shares of Urogen Pharma by 1,594.4% during the 3rd quarter. Russell Investments Group Ltd. now owns 3,321 shares of the company’s stock valued at $66,000 after purchasing an additional 3,125 shares during the period. Tower Research Capital LLC TRC grew its stake in shares of Urogen Pharma by 422.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 6,891 shares of the company’s stock valued at $94,000 after purchasing an additional 5,571 shares during the period. Nebula Research & Development LLC purchased a new stake in shares of Urogen Pharma during the 2nd quarter valued at about $162,000. Finally, Man Group plc bought a new position in shares of Urogen Pharma in the 2nd quarter worth approximately $196,000. Institutional investors own 91.29% of the company’s stock.

Urogen Pharma Company Profile

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.